Company intelligence / Profile preview
NeuClone
Sydney, New South Wales, Australianeuclone.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeuClone has completed Phase 1 clinical development for at least two monoclonal antibody biosimilars (including the ustekinumab biosimilar NeuLara and a trastuzumab biosimilar) showing comparable pharmacokinetics, safety, and immunogenicity to reference products; subsequent global Phase 3 development is planned or pursued with partners.
- Therapeutic areas
- ImmunologyEndocrinologyDermatologyInfectious DiseasesRheumatologyGastroenterologyOncology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Serum Institute of India (strategic manufacturing and co‑development collaboration for at least 10 biosimilars; Serum responsible for manufacture, clinical and commercial supply for defined territories)
Beyond the preview
Go deeper on NeuClone.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeuClone.